Day: April 9, 2024

Verkkokauppa.com hosts a Capital Markets Day on 30 May 2024 Verkkokauppa.com Oyj         INVESTOR NEWS                 9 April 2024 at 10.00am EEST Verkkokauppa.com, a Finnish pioneer of e-commerce, will arrange a Capital Markets Day on Thursday 30 May 2024 afternoon. At the event, the company’s management will discuss the cornerstones of the updated strategy to accelerate profitable growth and the journey toward financial targets during the strategy period. The event in Helsinki in Studio Eliel at Sanomatalo is intended for institutional investors, analysts and other capital markets and media representatives. All interested parties can follow the presentations through a live webcast. The presentations will be held in English. The actual invitation, a more detailed program and registration instructions will be published closer to the event. Verkkokauppa.com...

VANCOUVER, British Columbia, April 09, 2024 (GLOBE NEWSWIRE) — A.I.S. Resources Limited (TSX-V: AIS, OTC-PINK: AISSF, FRA: 5YHA) (the “Company” or “AIS”) announces a renewed focus on gold exploration in Australia.  Through its wholly owned Australian subsidiary AIS Resources Aust. Pty, AIS continues to own:100% interest in the 28 km2 Fosterville-Toolleen Exploration License (EL6001) located 10 km due east of Agnico Eagle’s Fosterville gold mine, 60% interest in the 58 km2 Bright Exploration License (EL6194), with an option to acquire 100%, and, 100% interest in the 167 km2 Kingston Exploration License (EL6318).These three advanced stage exploration properties, with a combined area of over 250 km2, are all located in the Lachlan Fold Belt, also known as the Golden Triangle, located in the Central Victoria region of Australia....

Atos announces the parameters of its refinancing framework, based on its full business perimeter of Tech Foundations and Eviden:€600 million of cash needed to fund the business over the 2024-25 period. Funds to be provided in the form of debt and/or equity by existing stakeholders or third-party investors€300 million in new revolving credit facility and €300 million in additional bank guarantee lines Targeting BB credit profile by 2026, which assumes a financial leverage1 below 3x by year-end 2025 and below 2x by year-end 2026 and implies a gross debt reduction of €2.4 billion Remaining debt maturities extended by 5 yearsExisting stakeholders of Atos SE and third-party investors can submit financing proposals including new money by April 26, 2024. Given the Group’s needs, a global refinancing agreement will trigger significant...

EINDHOVEN, the Netherlands, April 09, 2024 (GLOBE NEWSWIRE) — ONWARD Medical N.V. (Euronext: ONWD), the medical technology company creating innovative therapies to restore movement, function, and independence in people with spinal cord injury (SCI), today announced that Stifel, a US-based full-service investment bank, has initiated coverage of ONWARD Medical with a Buy rating and Target Price of EUR 12.00 per share. This is a premium of 140% to the closing price of EUR 5.00 on April 8, 2024. The initiation report was published April 8, 2024. Stifel joins four other banks whose analysts cover ONWARD Medical, all of which maintain Buy ratings and Target Prices at substantial premiums to the current share price. “Stifel’s initiation of coverage reflects the value they place on the strategic positioning of our brain-computer interface...

Trondheim, 9 April 2024: The Annual General Meeting of NORBIT ASA will be held on Monday 6 May 2024 at 4:00 pm CEST. The meeting will be held as a digital meeting only without physical attendance. Information about how to attend the meeting can be found at the company’s website and in the attached notice. Shareholders who are not able to attend the meeting are encouraged to vote in advance or submit a proxy form prior to the meeting. Attached please find the following documents:The notice of the general meeting, including the proposed resolutions The proposals from the nomination committee for the general meeting The guidelines for remuneration to the senior executives The board of directors’ report on salary and other remuneration for leading personnel for 2023All documents to be processed in the meeting, including access to electronic...

In 2024 Q1, 3.4 million tons of cargo and 1.5 million passengers passed through the harbours of the Port of Tallinn. Compared to the same period previous year, the number of passengers increased by 5% i.e. 69 thousand passengers, while the cargo volume remained at the same level. The number of vessel calls decreased by 5% to 1 627 calls. The number of passengers travelling between the Estonian mainland and the main islands increased by 6%, the number of vehicles also increased by 6%. The number of charter days of the icebreaker Botnica stayed at the previous year’s level, utility rate of the vessel was 100%. According to Valdo Kalm, chairman of the management board of Tallinna Sadam, we are pleased with the continued growth of the number of passengers and the stabilization of the cargo business. “The number of passengers continued...

Press ReleaseRegulated Information09 April 2024, 7:00 am CET, Antwerp, Belgium The shareholders of VGP NV (the “Company”) are hereby invited to attend the annual shareholders’ meeting and the special shareholders’ meeting of the Company which shall consecutively take place at The General, Business Centre, Generaal Lemanstraat 61, 2018 Antwerp, Belgium, on Friday 10 May 2024 at 10:00 am. Please consult the website link: www.vgpparks.eu/en/investors/shareholder-meetings/ for further information concerning the annual report (including portfolio overview, financial review and the corporate responsibility report), agenda, admission conditions and voting modalities for the Meetings. The board of directors CONTACT DETAILS FOR INVESTORS AND MEDIA ENQUIRIESInvestor Relations Tel: +32 (0)3 289 1433investor.relations@vgpparks.euKaren Huybrechts(Head...

Allschwil, Switzerland, April 09, 2024 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today that it has been awarded a grant from CARB-X (Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator), a global non-profit partnership dedicated to supporting the early development of antibacterial products. The grant award is to support initial preclinical activities on the antibiotics program recently acquired from Spexis. The initial funding of up to USD 0.9 million will support the work until candidate nomination in the second half of 2024. Basilea could receive additional funding from CARB-X, to continue preclinical and early clinical development of the antibiotics program, if the project...